Key result
Thalassemia major cohorts show ~82% survival to age 25, though endocrine and cardiac complications persist.
Cohort (n=1,146)
Answers are grounded in this paper and cite their sources.
Demonstrates improving long-term survival alongside high complication rates in thalassemia major, highlighting the persistent burden of endocrine and cardiac disorders.
We studied survival and disease complications in 1,146 patients with thalassemia major, born from January 1, 1960 to December 31, 1987. At last follow-up, in March 1997, probability of survival to age 20 years was 89% and to age 25 years was 82% for patients born in the years 1970-1974. Patients who died had a serum ferritin level, measured the year before death, significantly higher than those who survived. Diabetes was present in 5.4% of the patients; heart failure in 6.4%; arrhythmias in 5.0%, thrombosis in 1.1%, hypothyroidism in 11.6%, HIV infection in 1.8%. Hypogonadism was diagnosed in 55% of 578 patients who had reached pubertal age: 83.5% of hypogonadic females and 78.6% of males were receiving substitutive hormonal therapy. In conclusion, the survival of patients with thalassemia major is good and improving, but the prevalence of severe complications is still high.
No takes yet. Share an insight, caveat, or question.
Borgna‐Pignatti et al. (1998) conducted a cohort in Thalassemia major (n=1,146). Thalassemia major (birth cohort 1970-1974) was evaluated on Probability of survival to age 25 years (for 1970-1974 birth cohort). Patients with thalassemia major born in 1970-1974 had an 89% survival probability to age 20 and 82% to age 25, though complications like heart failure and hypogonadism remained common.
Synapse has enriched 10 related papers. Consider them for comparative context: